To determine the role of RGS6 in the development of NSCLC, we first analyzed The Cancer Genome Atlas (TCGA) dataset and discovered that the mRNA levels of RGS6 were significantly reduced in tumor tissues from LUAD (lung adenocarcinoma) and LUSC (lung squamous cell carcinoma) patients compared to normal counterparts (Fig. 1A). Here, RGS6 is linked to lung adenocarcinoma.